These findings suggest that platelet-based products, particularly PRP, may serve as effective and physiologically compatible alternatives to conventional chemical agents in pleurodesis. Furthermore, i-PRF represents a promising candidate in scenarios where minimizing inflammation is critical. This study is the first to evaluate i-PRF in pleurodesis and supports its potential translational application. Further clinical studies are warranted to validate these findings in human subjects.
Ancın et al. (Wed,) studied this question.